Author name: Leonardo Arias

The payments were made after a California arbitrator found private text messages between Orthofix executives couldn’t be considered cause for firing.

The layoffs across GSK’s Belgium sites come on the heels of the pharma’s planned shuttering of its German vaccine manufacturing site, which prompted job cuts for about 650 employees.

Since his release from prison in 2022, Martin Shkreli has traded stocks and publicly opined on news events, damaging reputations and sinking share prices for small biotechs including Capricor and Cassava, the FTC alleges.

Prosecutors say the company filled unnecessary prescriptions that fueled the opioid epidemic. A spokesperson for CVS said the company admitted to no wrongdoing and “strongly disagreed” with the case’s claims.

The nonprofits will merge on Nov. 1 after securing approval from state regulators, the systems announced this week.

Centene is the latest insurer to adopt a gold card program as states and the Trump administration push for prior authorization reform.

In a strategy shift, the company will invest in its procedural ultrasound business, supporting cardiovascular surgeries

Revolution Medicines’ recently approved drug showed a 24% overall response rate and a high rate of side effects in patients whose cancer has a G12D mutation, reinforcing Mizuho’s view that a more specific agent such as Verastem Oncology’s VS-7375 “should come first for G12D patients.”

The Gilead Sciences deal, which include $135 million in upfront and near-term payments, marks a critical platform validation for Vir Biotechnology as investors await an upcoming readout in solid tumors.

Obesity-focused Zealand Pharma is buying into Generate:Biomedicines’s generative AI platform to create new multispecific drug candidates.